NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in .
Article content
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a pre-injury baseline test requirement, announced today the granting of U.S. Patent No. 11,013,441 by the U.S. Patent and Trademark Office. This patent protects Oculogica’s method and system for assessing impairment due to cannabis and other substances, using a non-invasive eye-tracking system. This is Oculogica’s 8
th patent in the U.S. In addition to this patent, Oculogica is spearheading the largest clinical study ever conducted to evaluate the impact of cannabis on eye-tracking.